Psilocybin-Research.comSearchable psilocybin and psilocin bibliometrics.
Published

Control group improvement lower in psilocybin trials for depression

A meta-analysis comprising 17 randomized trials has found that rates of control group improvement in depression studies were lower in psilocybin trials than in studies of esketamine or a selective serotonin reuptake inhibitor (SSRI). The results suggest that psilocybin's overall efficacy in the treatment of depression might be overestimated.

Open source BibTeX RIS

Bibliographic context

Journal
The Brown University Psychopharmacology Update
Date
2025-10-09
Source
OpenAlex
DOI
10.1002/pu.31371
PubMed
Unavailable

Authors

Watch author

Topics and keywords

psilocybin DepressionReceptor PharmacologyClinical TrialRandomized Controlled TrialMeta-AnalysisTreatment-Resistant Depression Randomized Controlled Trial PsilocybinMedicineDepression (economics)Serotonin reuptake inhibitorRandomized controlled trialClinical trialInternal medicineSerotoninDepressive symptomsPsychiatryReuptake inhibitorAnesthesiaTreatment-resistant depressionClinical efficacyTreatment and control groupsHallucinogenSerotonin Uptake InhibitorsPsychedelics and Drug StudiesPsychotherapy Techniques and ApplicationsDigital Mental Health Interventions

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Control group improvement lower in psilocybin trials for depression2025-10-09

Related papers

Could psilocin rescue chronic, stress-accelerated, transcriptional aging in brain?UKnowledge (University of Kentucky) · 2025-03-03COMBINATION OF PSILOCYBIN AND COGNITIVE BEHAVIORAL THERAPY IMPROVES OXYTOCIN LEVELS AND DEPRESSIVE SYMPTOMS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDERGenetics and Molecular Research · 2025-12-31S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-18Repurposing of recreational drugs: will these new ‘medicines’ (e.g., psychedelics, psilocybin, cannabinoids, LSD, MDMA, ketamine) deliver short- or longer-term benefits for those with depressive or other mood disorders?Research Directions Depression · 2023-10-12Psilocybin may help cancer patients with depression and anxiety for yearsAccess Science · 2019-12-31The Utility of Psilocybin in Managing Anxiety and Depression in Cancer PatientsBiochemistry and Molecular Biology Education · 2018-07-31Psilocybin to Manage Cancer-Related DepressionUnknown journal · 2016-12-20Can Psilocybin Treat Severe DepressionJournal watch · 2017-11-02